Pfizer is currently investing into new biotechnological solutions for improvements of existing drugs. Rather than contain synthetically created chemical compounds, "biologics" derive their materials from living cells. Rather than create new drugs with the technology, companies like Pfizer and Merck plan to create similar versions of the drugs but sell them at lower costs.
While the compounds are generally far away from reaching the market, the article elucidates a whole new field of rival drugs from companies hoping to give more efficient, effective care by tapping into biotechnological techniques.
Source: http://online.wsj.com/article/SB10001424052748704464704575208580328253618.html?mod=rss_whats_news_us
No comments:
Post a Comment